Nanoviricides (NNVC) Common Equity (2011 - 2026)
Nanoviricides (NNVC) posted Common Equity of $9.2 million for Q1 2026, down 17.32% sequentially from $11.1 million in Q4 2025, and up 3.63% YoY from $8.8 million in Q1 2025.
Nanoviricides (NNVC) Common Equity (2011 - 2026) Analysis & Trends
Nanoviricides has reported Common Equity for 16 years, with the latest figure at $9.2 million in Q1 2026.
- Quarterly Common Equity rose 3.63% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 3.63% YoY) and the FY2025 annual result came in at $7.5 million, down 34.43% from the prior year.
- Common Equity declined to $9.2 million in Q1 2026 per NNVC's latest filing, from $11.1 million in the prior quarter.
- Over five years, Common Equity peaked at $24.8 million in Q1 2022 and troughed at $7.2 million in Q3 2025.
- A 5-year average of $13.8 million and a median of $11.5 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 41.56% in 2024, then increased 6.6% in 2025.
- Over 5 years, Common Equity stood at $19.9 million in 2022, then sank by 37.34% to $12.5 million in 2023, then declined by 16.58% to $10.4 million in 2024, then advanced by 6.6% to $11.1 million in 2025, then decreased by 17.32% to $9.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $9.2 million, $11.1 million, and $7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 9.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.15 Mn |
| Dec 31, 2025 | 11.07 Mn |
| Sep 30, 2025 | 7.17 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Dec 31, 2024 | 10.39 Mn |
| Sep 30, 2024 | 10.11 Mn |
| Jun 30, 2024 | 11.46 Mn |
| Mar 31, 2024 | 10.65 Mn |
| Dec 31, 2023 | 12.45 Mn |
| Sep 30, 2023 | 12.97 Mn |
| Jun 30, 2023 | 14.87 Mn |
| Mar 31, 2023 | 18.23 Mn |
| Dec 31, 2022 | 19.87 Mn |
| Sep 30, 2022 | 21.56 Mn |
| Jun 30, 2022 | 23.08 Mn |
| Mar 31, 2022 | 24.76 Mn |
| Dec 31, 2021 | 26.47 Mn |
| Sep 30, 2021 | 28.31 Mn |
| Jun 30, 2021 | 29.91 Mn |